46.36
1.52 (3.39%)
| Previous Close | 44.84 |
| Open | 45.42 |
| Volume | 2,378,212 |
| Avg. Volume (3M) | 3,046,248 |
| Market Cap | 8,554,810,880 |
| Price / Earnings (Forward) | 2.50 |
| Price / Sales | 4.88 |
| Price / Book | 4.05 |
| 52 Weeks Range | |
| Earnings Date | 31 Jul 2024 |
| Profit Margin | -6.70% |
| Operating Margin (TTM) | -3.13% |
| Diluted EPS (TTM) | -0.950 |
| Quarterly Revenue Growth (YOY) | 12.40% |
| Total Debt/Equity (MRQ) | 87.21% |
| Current Ratio (MRQ) | 2.17 |
| Operating Cash Flow (TTM) | 118.66 M |
| Return on Assets (TTM) | -2.71% |
| Return on Equity (TTM) | -5.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Exact Sciences Corporation | Bullish | Bearish |
Stockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.30 |
|
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, or MRD, colorectal cancer screening, and multicancer screening. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Growth |
| % Held by Insiders | 1.00% |
| % Held by Institutions | 98.56% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 85.00 (Piper Sandler, 83.35%) | Buy |
| Median | 77.50 (67.17%) | |
| Low | 67.00 (Benchmark, 44.52%) | Buy |
| Average | 77.33 (66.80%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 62.78 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Evercore ISI Group | 01 Oct 2024 | 80.00 (72.56%) | Buy | 68.04 |
| Canaccord Genuity | 13 Sep 2024 | 75.00 (61.78%) | Buy | 65.54 |
| Piper Sandler | 12 Sep 2024 | 85.00 (83.35%) | Buy | 67.39 |
| Wells Fargo | 27 Aug 2024 | 75.00 (61.78%) | Buy | 59.89 |
| Benchmark | 01 Aug 2024 | 67.00 (44.52%) | Buy | 57.91 |
| Stifel | 01 Aug 2024 | 82.00 (76.88%) | Buy | 57.91 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BARANICK BRIAN | - | 68.57 | -929 | -63,702 |
| Aggregate Net Quantity | -929 | |||
| Aggregate Net Value ($) | -63,702 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 68.57 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BARANICK BRIAN | Officer | 08 Oct 2024 | Automatic sell (-) | 929 | 68.57 | 63,702 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |